
    
      This is a Phase 2 study designed to evaluate the efficacy and safety of ABT-126 in
      approximately 260 adults with mild-to-moderate Alzheimer's disease (AD). Subjects will be
      randomized to one of the four treatment groups (ABT-126, donepezil, or placebo) for a 12-week
      Treatment Period. Acronyms are listed in the secondary outcome section, below, you will find
      a list of the acronyms defined:

        -  MMSE - Mini Mental Status Exam

        -  QoL-AD - Quality of Life - Alzheimer's Disease

        -  CIBIC-plus - Clinician Interview-Based Impression of Change

        -  NPI - Neuropsychiatric Inventory

        -  CSDD - The Cornell Scale for depression in Dementia

        -  ADCS-ADL - Alzheimer's Disease Cooperative Study - Activities of Daily Living
    
  